Montana advances plan to become experimental drug hub
Healthy individuals can access unapproved treatments for a fee under new rules
1Montana's radical healthcare vision
Montana established a new system facilitating access to experimental drugs. Biotech companies can apply for $12,500 to sell drugs tested on as few as 10 healthy volunteers. After approval by a review board, these drugs can be sold even to healthy individuals without terminal illness. The first clinics are expected to launch by late 2025.
2Regulatory details
Montana's Health Department implemented new rules on July 25. Patients must provide informed consent. Applications will be reviewed by a board including a Montana-licensed physician, scientists, and an ethicist. Board members will be funded by application fees. Supporters emphasize the process will be rigorous.
3Role of longevity enthusiasts
The law was shaped by longevity researchers rather than traditional patient advocacy groups. In 2023, Senator Ken Bogner removed the terminal illness requirement. Organizations like Alliance for Longevity Initiatives (A4LI) supported the effort. Entrepreneur Niklas Anzinger shifted focus from a similar project in Honduras to Montana's model.
4First review board established
Infinita announced Montana ETRB, the first independent review board. It includes oncologist James Burke, bioethicist Jessica Flanigan, and three longevity experts. Board members claim independence from Infinita. The company updated its website after criticism about appearing as a government entity.
5Criticisms and concerns
Experts like Harvard's Aaron Kesselheim express concerns about selling non-FDA-approved drugs. Traditional medical circles question safety, especially for preventive treatments. Supporters defend informed adults' right to choose. Montana's model is likely to reignite debates about experimental treatment access in the US.
6Clinic operations
Clinics selling non-FDA-approved drugs must register under Montana law. Each application will be individually reviewed. Patients will receive detailed information and provide written consent. Pricing will be at companies' discretion. The first clinics are planned to open by year-end.
7Opportunity for biotech firms
Montana offers a new market for early-stage drugs. Companies can directly commercialize products completing phase 1 trials. The model particularly appeals to rare disease and anti-aging startups. Ethical concerns increase reputational risks, while supporters argue it accelerates innovative treatments.
8Honduras connection
Project leader Niklas Anzinger previously established a similar clinic in Honduras' Prospera special economic zone. His Infinita City community offered experimental stem cell and gene therapies. Anzinger shifted focus to the US, considering Montana's regulatory framework more suitable. The Honduras experience informs Montana's implementation.
9Legal evolution
Montana's 'right-to-try' laws began in 2015 for terminal patients. The scope expanded in 2023. A second law in April 2025 established clinic operational rules. The Health Department's implementation rules took effect in July. The process represents an interesting collaboration between state legislature and private sector.
10Bioethics debate
Libertarian thinkers like Jessica Flanigan support the law, emphasizing individual autonomy. Opponents warn about potential exploitation of vulnerable individuals. Scientific validity of 'longevity' claims is questioned. Montana's model reignites tensions between 'do no harm' principle and personal freedom in medical ethics.
11Economic model
Infinita funds the review board through $12,500 application fees. Clinics will operate for profit. Supporters argue the system funds innovative treatments, while critics warn commercial interests might override patient safety. The model's sustainability remains untested.
12National implications
Montana's move could set precedent for those frustrated with FDA's strict approval process. Similar legislation may emerge in other states. The experimental treatment market, especially in anti-aging and rare diseases, could expand. Federal regulators' response remains uncertain. Montana might be initiating a new paradigm in US healthcare.
Original article: MIT Technology Review — Montana, deneysel ilaç pazarında öncü olma yolunda